Other Corporate Information – Page 5

2023-06-26

Regulatory

Alligator Bioscience Announces Positive Second Interim Efficacy Analysis from Mitazalimab OPTIMIZE-1 Phase 2 Study in 1st Line Pancreatic Cancer

Continued follow-up on the futility analysis cohort (23 patients) showed deepening of tumor responses and an increase in Objective Response ...

2023-06-13

June 27, 2023 – 9:00 AM ET / 3:00 PM CET Featuring Dr. Zev Wainberg from UCLA Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) ...

2023-06-05

Mitazalimab achieved 52% Objective Response Rate when combined with mFOLFIRINOX in 1st line pancreatic cancer and passed the futility analys ...

2023-05-18

Regulatory

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O ...

2023-05-11

Regulatory

Orion selects lead antibodies from the first discovery program Collaboration aims to discover and develop new bispecific antibody cancer the ...

2023-04-282023-04-28

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2023-04-27

REACTIVE-2 is assessing the safety and immunological effect of mitazalimab in combination with MesoPher in metastatic pancreatic cancer Mita ...

2023-04-18

Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors Data strongl ...

2023-04-12

OPTIMIZE-1 is assessing the safety and efficacy of mitazalimab in combination with mFOLFIRINOX in 1st line metastatic pancreatic cancer Inte ...